At Dr Sudhir’s Pain Relief Clinic, we keep you informed on pivotal medical advancements—because true relief isn’t just about alleviating pain today, but safeguarding your health long‑term. One such groundbreaking development is the indigenous malaria vaccine candidate, AdFalciVax, currently being developed under the aegis of the Indian Council of Medical Research (ICMR). X (formerly Twitter)+8The Tribune+8The Economic Times+8

What Is AdFalciVax?

• Recombinant, chimeric multi‑stage vaccine: Engineered to combat two critical phases of Plasmodium falciparum—the infection stage in humans and the transmission stage via mosquitoes. X (formerly Twitter)+7Deccan Chronicle+7The Times of India+7

• First fully indigenous effort: Developed collaboratively by ICMR’s Regional Medical Research Centre (RMRC), Bhubaneswar; National Institute of Malaria Research (NIMR); and DBT‑National Institute of Immunology (NII) in New Delhi. @mathrubhumi+4The Tribune+4The Times of India+4

Why It Matters

• Preclinical promise: Demonstrated “excellent efficacy” in early lab trials and may outperform existing single‑stage vaccines by offering broader protection, lowering immune evasion risk, and potentially enabling better long‑term immunity. @mathrubhumi+4Deccan Chronicle+4The Economic Times+4

• High thermal stability: Designed to be functional at room temperature for over nine months—crucial for deployment in tropical regions. The Economic Times+3@mathrubhumi+3The Tribune+3

• Cost-effective & scalable: Produced in Lactococcus lactis and formulated with alum as an adjuvant—affordable, scalable, and aligned with “Make in India” goals. The Tribune+4@mathrubhumi+4Deccan Chronicle+4

What’s Next?

• Technology licensing: ICMR has invited expressions of interest from pharma companies to license the vaccine technology under non‑exclusive agreements—for further development, manufacturing, and commercialization. The Economic Times+7Deccan Chronicle+7The Times of India+7

• Clinical trial timeline: With preclinical success complete, ICMR aims to initiate Phase 1 trials within approximately two years. Full regulatory clearance and rollout could follow in subsequent years. Deccan Chronicle

Relevance to Our Community

Although malaria is not typically associated with chronic pain, repeated infections can have long-lasting effects—fatigue, joint pain, muscle ache, even organ damage—all of which align with the patient profiles at Dr Sudhir’s Pain Relief Clinic. Vaccines like AdFalciVax have the potential to reduce these long-term risks by preventing infections in the first place.

A Holistic Approach to Health

Our commitment extends beyond immediate pain management. We champion preventive measures—vaccines, nutrition, lifestyle—to ensure lasting wellness. A future with fewer malaria cases means fewer chronic repercussions, less suffering, and healthier lives.

Stay Informed. Stay Protected.

Dr Sudhir’s Pain Relief Clinic will continue monitoring AdFalciVax’s progress—especially when clinical trial phases begin. If you or a loved one has questions about malaria prevention, post-infection care, or vaccine information, our team is ready to help.

🔔 Stay Informed. Stay Empowered. Subscribe & Join Now:

📲 YouTube Channel
📱 WhatsApp Channel

We regularly share important health updates, prevention tips, and pain management strategies you can trust. Be part of our community that’s always one step ahead in health awareness and care.